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A DNA methylation biomarker of alcohol consumption
C Liu1,2,3,55, RE Marioni4,5,6,55, ÅK Hedman7,55, L Pfeiffer8,9,55, P-C Tsai10,55, LM Reynolds11,55, AC Just12,55, Q Duan13,55, CG Boer14,55,
T Tanaka15,55, CE Elks16, S Aslibekyan17, JA Brody18, B Kühnel8,9, C Herder19,20, LM Almli21, D Zhi22, Y Wang23, T Huan1,2, C Yao1,2,
MM Mendelson1,2, R Joehanes1,2,24, L Liang25, S-A Love23, W Guan26, S Shah6,27, AF McRae6,27, A Kretschmer8,9, H Prokisch28,29,
K Strauch30,31, A Peters8,9,32, PM Visscher4,6,27, NR Wray6,27, X Guo33, KL Wiggins18, AK Smith21, EB Binder34, KJ Ressler35, MR Irvin17,
DM Absher36, D Hernandez37, L Ferrucci15, S Bandinelli38, K Lohman11, J Ding39, L Trevisi40, S Gustafsson7, JH Sandling41,42, L Stolk14,
AG Uitterlinden14,43, I Yet10, JE Castillo-Fernandez10, TD Spector10, JD Schwartz44, P Vokonas45, L Lind46, Y Li47, M Fornage48,
DK Arnett49, NJ Wareham16, N Sotoodehnia18, KK Ong16, JBJ van Meurs14, KN Conneely50, AA Baccarelli51, IJ Deary4,52, JT Bell10,
KE North23,56, Y Liu11,56, M Waldenberger8,9,56, SJ London53,56, E Ingelsson7,54,56 and D Levy1,2,56
The lack of reliable measures of alcohol intake is a major obstacle to the diagnosis and treatment of alcohol-related diseases.
Epigenetic modiﬁcations such as DNA methylation may provide novel biomarkers of alcohol use. To examine this possibility, we
performed an epigenome-wide association study of methylation of cytosine-phosphate-guanine dinucleotide (CpG) sites in relation
to alcohol intake in 13 population-based cohorts (ntotal = 13 317; 54% women; mean age across cohorts 42–76 years) using whole
blood (9643 European and 2423 African ancestries) or monocyte-derived DNA (588 European, 263 African and 400 Hispanic
ancestry) samples. We performed meta-analysis and variable selection in whole-blood samples of people of European ancestry
(n = 6926) and identiﬁed 144 CpGs that provided substantial discrimination (area under the curve = 0.90–0.99) for current heavy
alcohol intake (⩾ 42 g per day in men and ⩾ 28 g per day in women) in four replication cohorts. The ancestry-stratiﬁed
meta-analysis in whole blood identiﬁed 328 (9643 European ancestry samples) and 165 (2423 African ancestry samples)
alcohol-related CpGs at Bonferroni-adjusted P o1 × 10 − 7. Analysis of the monocyte-derived DNA (n = 1251) identiﬁed 62
alcohol-related CpGs at P o1 × 10-7. In whole-blood samples of people of European ancestry, we detected differential methylation
in two neurotransmitter receptor genes, the γ-Aminobutyric acid-A receptor delta and γ-aminobutyric acid B receptor subunit 1; their
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differential methylation was associated with expression levels of a number of genes involved in immune function. In conclusion, we
have identiﬁed a robust alcohol-related DNA methylation signature and shown the potential utility of DNA methylation as a
clinically useful diagnostic test to detect current heavy alcohol consumption.
Molecular Psychiatry (2018) 23, 422–433; doi:10.1038/mp.2016.192; published online 15 November 2016

INTRODUCTION
Each year, nearly 2.5 million deaths worldwide are attributable to
alcohol use.1 Most alcohol-attributable diseases and injuries occur
in people without a diagnosed alcohol use disorder.2–5 Researchers have attempted to develop laboratory tests to detect heavy
drinkers who are more reliable than self-reported alcohol intake
(e.g. alcohol screening questionnaires). In addition, a biomarker
would be useful in epidemiologic studies of health effects of
alcohol as an objective measure to supplement and validate selfreported data. It could also prove useful in studies of other
exposures where careful adjustment for alcohol intake is needed.6
Several biochemical measurements, such as serum alanine
transaminase (ALT) and aspartate transaminase (AST) levels have
been used to assess heavy alcohol use. However, the discriminatory ability of these biomarkers is far from ideal, with the area
under the curve (AUC) to predict heavy alcohol consumption
ranging from 0.21 to 0.67.7 The addition of four protein markers,
AT-rich interactive domain-containing protein 4B (ARID4B),
phosphatidylcholine-sterol acyltransferase (LCAT), hepatocyte
growth factor-like protein (MST1) and ADP-ribosylation factor 6
(ARL6), improved AUC values for the detection of heavy drinkers
to 0.73–0.86, leaving room for further improvement.7
Emerging evidence suggests that alcohol consumption inﬂuences epigenetic modiﬁcations,8–10 which in turn can affect gene
expression levels.8,11,12 Methylation of the cytosine position in
CpGs is among the best-characterized epigenetic modiﬁcations.13
To date, more than 20 studies have been conducted to identify
alcohol-related DNA methylation signatures. Most of these studies,
however, have focused on alcohol dependence in relation to
‘global’ methylation levels or preselected candidate genes14 and
only a few studies have used epigenome-wide approaches.15–18
The largest genome-wide study so far included about 700
individuals.16 To date, limited sample sizes have hindered the
search for a robust alcohol-related DNA methylation signature.
Hence, there is a need for a large-scale collaborative effort to
determine the association of alcohol consumption with DNA
methylation across the genome. Here we demonstrate that DNA
methylation can be used as a highly predictive blood biomarker to
detect heavy alcohol drinking. We also report meta-analysis results
from epigenome-wide association studies (EWAS) in up to 13 317
individuals from 13 cohorts in which DNA methylation was measured
in blood samples using the Inﬁnium HumanMethylation450
BeadChip (Illumina, San Diego, CA, USA). Third, we determined
the genetic contributions to alcohol-related methylation
differences. Finally, we explored the functional implications of
alcohol-related differential methylation by testing its association
with gene expression in blood.
MATERIALS AND METHODS
Study population
This analysis included 13 317 participants from 13 population-based
prospective cohorts of the Cohorts for Heart and Aging Research in
Genomic Epidemiology Consortium plus (CHARGE+) Consortium. These
cohorts were sampled from free-living members of the community, but
they were all not required to be healthy nor were they selected based on
disease. During follow-up, some participants developed health conditions
such as cardiovascular diseases (CVDs) and cancer. About 54% of
participants were women and the average age was from 42 to 76 years

old across the cohorts (Table 1). The patterns of alcohol consumption
varied widely across the cohorts. For nine cohorts, fewer than one-third of
participants reported no current alcohol intake and for four cohorts more
than 50% of participants reported no current alcohol intake. The high
proportion of non-drinkers in these four cohorts is in line with other
studies of people of comparable age, birth cohort and gender mix. Heavy
drinkers, deﬁned below, represented 2–17% of participants across studies
(Table 1). Informed consent for genetic studies was obtained from all
subjects. The protocol for each study was approved by the institutional
review board of each cohort.

Alcohol traits
Alcohol consumption was measured by self-administered questionnaires
or structured interview with a trained psychologist at the same period
when blood samples were obtained for DNA methylation quantiﬁcation.
Alcohol consumption measured the total consumption of beer, wine and
spirits. For American cohorts, a drink was deﬁned as 12 ounces of beer,
4–5 ounces of wine or 1.5 ounces of liquor, where one drink is equivalent
to ~ 14 g of ethanol. For European cohorts, a slightly different deﬁnition of
‘a drink’ and its conversion to grams of ethanol was used (Supplementary
Information: pp 14–16, 19–22 in Description of study samples). The
continuous exposure variable was deﬁned as the average grams of ethanol
consumed per day (g per day) over the course of a year during the period
when the blood sample was collected for DNA methylation quantiﬁcation.
The continuous variable was further categorized into four drinking
categories. ‘Non-drinkers’ were subjects with no alcohol consumption
(i.e., g per day = 0); ‘light drinkers’ were subjects who consumed 0 og
per day ⩽ 28 in men and 0 og per day ⩽ 14 in women; ‘at risk-drinkers’
were subjects who consumed 28og per dayo 42 in men and 14 og
per dayo 28 in women; ‘heavy drinkers’ were subjects who consumed
⩾ 42 g per day in men and ⩾ 28 g per day in women.
To explore the effects of ‘former’ alcohol drinking on DNA methylation,
we examined alcohol consumption at prior examinations for all current
non-drinkers (n = 693, see Table 1) in the Framingham Heart Study (FHS)
because information on prior drinking was not available in the majority of
other cohorts. We classiﬁed non-drinkers in FHS into ‘never’ drinkers and
‘former’ drinkers. ‘Never’ drinkers were individuals who self-reported no
alcohol consumption at any prior examination; ‘former’ drinkers were
individuals who reported alcohol consumption at any prior examination.
For ‘former’ drinkers, we calculated their alcohol consumption (‘g per day’)
at each prior examination.

DNA methylation quantiﬁcation and quality control
DNA was extracted from whole-blood (n = 9643 European (EA) and 2423
African ancestry (AA)) and CD14+ monocyte (n = 1251 of mixed EA
(n = 588), AA (n = 263) and Hispanic ancestry (n = 400) samples (Table 1 and
Supplementary Information). Detailed information about DNA extraction,
bisulﬁte conversion, methylation proﬁling, normalization and quality
control (QC) procedures can be found in Supplementary Information.
Study samples were excluded from analysis if they had a missing rate of
41–5% across methylation probles; poor single nucleotide polymorphism
(SNP) matching compared with previous genotyping of the 65 SNPs
included on the methylation array; or sample outliers identiﬁed by
multidimensional scaling techniques. The methylation probes were
excluded if they were the 65 SNP probes, or probes that were previously
identiﬁed to map to multiple locations (n = 29 233);19 had average
detection P40.01 (the detection P-value indicates the probe performance);
had an underlying SNP within 10 bp of that probe or if the minor allele
frequency (MAF) of the underlying SNP was 45% in the 1000 Genomes
Project data (n = 15 178).19 After these ﬁltering procedures, ~ 440 000 DNA
methylation probes remained for subsequent analyses.
Molecular Psychiatry (2018), 422 – 433
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Study

Characteristics of the study participants

N

Men (%)

Age (years), mean (s.d.) BMI mean (s.d.) Current smoking (%)

g per day, Median
(min, max)

Non-drinkers (%) Light drinkers (%) At-risk drinkers (%) Heavy drinkers (%)

European ancestry whole blood (n = 9643)
CHS
185
84 (45)
EPIC-Norfolk 1275 650 (51)
FHS
2427 1095 (45)
InCHIANTI
499
225 (45)
KORA F4
1797 877 (49)
LBC1936
920
465 (51)
NAS
623
623 (100)
PIVUS
818
412 (50)
RS
502
241 (48)
TwinsUK
597
0 (0)

76
60
66
63
60
70
72
70
58
56

African ancestry whole blood (n = 2423)
ARIC
2003 721 (36)
CHS
190
66 (35)
GTP
230
76 (33)

56 (6)
73 (5)
42 (12)

30 (6)
29 (5)
32 (8)

490 (24)
29 (15.3)
74 (39)

0 (0, 301)
0 (0, 74)
14 (0,143)

1519 (76)
123 (65)
45 (20)

67 (3)
61(32)
113 (49)

69 (3)
2 (1)
NA

348 (17)
4 (2)
72 (31)

CD14+ monocytes (n = 1251)
MESA
1251 606 (48)

60 (9)

30 (6)

114 (9%)

8 (0, 191)

691 (55)

444 (36)

65 (5)

51 (4)

(5)
(9)
(9)
(16)
(9)
(1)
(7)
(0.2)
(7)
(9)

27
27
28
27
28
28
28
27
27
27

(5)
(4)
(5)
(4)
(5)
(4)
(4)
(4)
(5)
(5)

16
191
304
94
262
103
27
75
137
57

(9)
(15)
(13)
(19)
(15)
(11)
(4)
(9.2)
(27)
(10)

0
3
4
8
7
7
6
6.7
14
2

(0, 99)
(0, 98)
(0, 181)
(0, 161)
(0, 150)
(0,158)
(0, 93)
(0, 61)
(0, 88)
(0,59)

104
271
693
106
534
181
148
142
10
189

(56)
(21)
(29)
(21)
(29)
(20)
(24)
(17)
(2)
(31)

59
865
1260
265
751
574
385
639
366
375

(32)
(68)
(52)
(53)
(42)
(62)
(62)
(78)
(73)
(63)

7
79
280
70
282
104
52
32
84
22

(4)
(6)
(11)
(14)
(16)
(11)
(8)
(4)
(17)
(4)

15
60
194
58
230
61
38
5
42
11

(8)
(5)
(8)
(12)
(13)
(7)
(6)
(1)
(8)
(2)

Abbreviations: ARIC, The Atherosclerosis Risk in Communities study; BMI, body mass index; CHS, The Cardiovascular Health Study; EPIC-Norfolk, The European Prospective Investigation into Cancer-Norfolk
study; FHS, The Framingham Heart Study; GTP, The Grady Trauma Project; KORA F4, The Cooperative Health Research in the Region of Augsburg study; InCHIANTI, Invecchiare in Chianti; LBC1936, The Lothian
Birth Cohort 1936; MESA, The Multi-Ethnic Study of Atherosclerosis; NAS, The Normative Aging Study; PIVUS, The Prospective Investigation of the Vasculature in Uppsala Seniors Study; RS, The Rotterdam Study;
TwinsUK, The TwinsUK Study. The drinking categories were deﬁned based on grams of alcohol consumed per day (g per day): non-drinkers, g per day = 0; light drinkers, 0 o – ≤ 28 g per day in men and
0 o– ≤ 14 g per day in women; at-risk drinkers, 28 o–o 42 g per day in men and 14 o– o28 g per day in women; and heavy drinkers, g per day ≥ 42 in men and ≥ 28 in women. The Monocyte samples
included mixed samples of European (47%), African (21%) and Hispanic (32%) ancestries.
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Methylation analysis

Other types of analyses

DNA bisulfite conversion

Study samples

Methylation measured
using the Infinium
HumanMethylation450
BeadChip

Whole blood DNA
European ancestry (n=9,643)
African ancestry (n=2,423)
CD14+ monocytes (n=1,251)

Quality control

Genotypes: 1000g
imputation; minor allele
frequency > 0.05 and
imputation quality>0.5

Gene expression (Affymetrix
Human Exon Array ST 1.0 and
Illumina Human HT-12 v3 )

Epigenome-wide association analysis in each cohort
Primary: DNAm = g per day + age + sex + BMI + technical covariates + WBCs
Secondary: DNAm = I (light/at-risk/heavy drinkers versus non-drinkers) + age + sex + BMI
+ technical covariates +WBCs

Biomarker analysis
Discovery meta-analysis of whole
blood samples of EA ancestry
excluding LBC1936 and KORA F4

Analysis of methylation signature
1.

Ancestry-specific meta-analysis of
whole blood samples

2.

Meta-analysis of pooled samples of
whole blood and monocyte samples

P<5x10-6
Significance =P<1x10-7`

LASSO analysis in FHS (the training set) to
select CpGs to be used as a biomarker

1. Association between alcohol-related CpGs and

Test the selected CpGs in the training
cohort (FHS) and the replication cohorts
(KORA F4, LBC1936, ARIC and MESA) for
1.

Variance explained in the continuous
alcohol consumption trait

2.

ROC analysis-heavy drinkers versus
non-drinkers/light drinkers

•

cis-SNPs within 100 kb

•

mRNA levels of cis-genes within 1 Mb

2. Association between two CpGs in gamma aminobutyric acid (GABA) receptor genes and
genome-wide mRNA levels
3. Gene Ontology analysis to evaluate the
enrichment of genes in biological processes

Figure 1. Overview of the study design. ARIC, The Atherosclerosis Risk in Communities study; BMI, body mass index; DNAm, DNA methylation
value; FHS, the Framingham Heart Study; I (light/at-risk/heavy drinkers versus non-drinkers), the indicator variable for light drinkers versus
non-drinkers, at-risk drinkers versus non-drinkers and heavy drinkers versus non-drinkers; KORA F4, The Cooperative Health Research in the
Region of Augsburg study; LASSO, least absolute shrinkage and selection operator; LBC, The Lothian Birth Cohort; MESA, The Multi-Ethnic
Study of Atherosclerosis; WBCs, white blood cell counts.

Clinical and laboratory phenotypes
Age, height and weight were measured using standard protocols
implemented at the time DNA samples were collected. Body mass index
(BMI) was calculated as weight (kg) per height (m) squared. Smoking was
determined by self-report. Current smokers were deﬁned as smokers of at
least 1 cigarette per day over the course of a year at the time of blood
sample collection for methylation quantiﬁcation.
In the FHS cohort, the serum AST and ALT levels were measured on
fasting morning samples using the kinetic method20 at the same
examination cycle when whole blood was obtained for DNA methylation
measurement. ALT and AST were set to 5 if their measured levels were
o5 U l − 1. An individual was deﬁned as having CVD if he or she had
coronary heart disease, myocardial infarction, atherothrombotic infarction
of brain or congestive heart failure. A cancer phenotype was deﬁned if the
person had any type of cancer. Both CVD and cancer phenotypes were
deﬁned at the time of blood collection for measuring DNA methylation.

Statistical analysis
Epigenome-wide association studies. In each cohort, the primary EWAS
model used a DNA methylation β-value (the ratio of methylated probe
intensity divided by the sum of the methylation and unmethylated probe
intensity) as the outcome variable and the continuous alcohol trait
(g per day) as the predictor variable of interest. Because it has been shown
that many CpG sites are signiﬁcantly associated with age,21 sex22 and

BMI,23 these three variables were adjusted for in EWAS analysis.
Furthermore, it has been known that DNA methylation proﬁling is
susceptible to batch effects24 and by white cell composition in whole
blood.25 Thus, ‘batch effects’ and ‘white cell blood counts’ were adjusted
for to minimize confounding effects that may result in spurious association.
To account for batch effects, ‘lab’, ‘experiment date’, ‘plate’, ‘row’ and
‘column’ were adjusted for in the analyses. The measured or imputed25
white blood cell counts for CD4 cells, CD8 cells, natural killer cells,
B cells and monocytes were adjusted for in the analyses. Surrogate
variables (to account for unknown confounders)26 or principal components
(estimated from genotypes to account for population stratiﬁcation)27were
included in the EWAS model when applicable (pp 10, 11 and 15 of
Description of study samples in Supplementary Information). In the
secondary analysis, we used the categorical alcohol intake as the predictor
adjusting for the same covariates described above. The non-drinker
category was used as the reference group. We used a linear model in
unrelated individuals or a linear mixed model in family samples to account
for familial correlation in the association of DNA methylation and alcohol
consumption.
It is unclear if smoking confounds the relationship between alcohol
intake and DNA methylation or if smoking and alcohol intake are
associated with common CpGs. Therefore, we performed an additional
sensitivity analysis with and without current smoking status as a covariate
in drinker-only samples. We compared the change in the regression
coefﬁcient for the continuous alcohol intake trait when including current
Molecular Psychiatry (2018), 422 – 433
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smoking in the model compared with the regression coefﬁcient when
smoking was not included in the model using the following equation:
Δβalcoholsmk ¼ 100%  ðβalcoholsmk - βalcoholnosmk Þ
We performed sensitivity tests in the FHS data to investigate if CVD and
cancer confounded the relationship between DNA methylation and
alcohol consumption. The sensitivity test compared the regression
coefﬁcients and P-values between methylation and alcohol intake in a
EWAS model that did not adjust for CVD or cancer status to a second
model that adjusted for CVD or cancer status. Other covariates included
age, sex, BMI, batch effects and white blood cell counts.

DNA methylation as a biomarker in predicting alcohol
consumption
We performed the following four-step analyses to investigate if DNA
methylation can be used as a biomarker in discriminating alcohol
consumption categories (Figure 1).
Step 1: To establish independent replication cohorts, we split the wholeblood DNA samples from 10 cohorts of (EA (n = 9643; Table 1) into separate
discovery and replication sets. The discovery set consisted of eight EA
cohorts (n = 6926), excluding the Lothian Birth Cohort 1936 (LBC1936) and
Cooperative Health Research in the Region of Augsburg (KORA F4) study
(Table 1). We performed a meta-analysis in the eight EA cohorts using an
inverse-variance weighted random-effects model and selected CpGs at a
relaxed threshold Po5 × 10 − 6.
Step 2: To minimize overﬁtting and to explore which CpGs are more
important for including in a biomarker of alcohol consumption, we
performed least absolute shrinkage and selection operator (LASSO)
regression in the FHS cohort as a training set:
X
ResidCpG þ age þ sex þ BMI
log ðg per day þ 1Þ ¼
n¼1

In the above formula, all CpGs at Po 5 × 10 − 6 were included simultaneously in the LASSO analysis. Because alcohol consumption was right
skewed and contained non-drinkers, the log-transformed alcohol consumption (log (g per day+1)) was used as the outcome. To minimize
potential confounding effects in selecting a set of CpGs as a biomarker, we
obtained the residuals for each CpG in a linear regression model
(CpG = age+sex+BMI+batch effects+white blood cell counts). Here variables for ‘batch effects’ and ‘white blood cell counts’ were the same as the
variables used in EWAS analysis. In the LASSO analysis, we selected four
sets of CpGs using s = ‘lambda.min’, ‘lambda.1se’, 0.08 and 0.12. The
criterion s = ‘lambda.min’ selected the largest number of CpGs and s = 0.12
yielded the most parsimonious set of CpGs. We removed CpGs if they are
not on the Inﬁnium MethylationEPIC BeadChip (Illumina), which will
replace the Illumina Inﬁnium HumanMethylation450 BeadChip.
Step 3: In the FHS training set, we ﬁrst estimated the proportion of
variance in continuous alcohol consumption explained by the selected
CpGs. The adjusted R2 was estimated for the ‘Null’ model log
(g
Pper day + 1) = age + sex + BMI and the ‘Full’ model log (g per day + 1) =
ResidCpG + age + sex + BMI. The proportion of variance explained by a
n¼1

set of CpGs was the difference of adjusted R2 between the ‘Full’ and
‘Null’
models:
adjR2CpGs ¼ adjR2ageþsexþBMIþCpGs - adjR2ageþsexþBMI .
Discrimination of heavy alcohol consumption from non-drinkers or light
drinkers was our main focus. Therefore, we generated receiver-operating
characteristic curves (ROC) in the FHS training cohort to evaluate the
performance of these four sets of CpGs in classifying current heavy
drinkers versus (1) non-drinkers, (2) light drinkers and (3) pooled
individuals of light or non-drinkers. In addition, we evaluated if these
CpGs can be used in classifying individuals in the following comparisons:
(4) heavy drinkers versus at-risk-drinkers; (5) at-risk drinkers versus nondrinkers; (6) at-risk drinkers versus light drinkers; and (7) light drinkers
versus non-drinkers. In all comparison pairs, the former category was the
‘disease’ group and the latter was the ‘control’ group. In ROC analysis, the
expected probability of being ‘diseased’ was calculated using logistic
regression in which the ‘disease’ (1/0) was used as the outcome variable,
and age, sex and BMI without or with a set of CpGs (residuals) as
independent variables. Sensitivity, speciﬁcity and the AUC for classifying
‘diseased’ individuals versus ‘controls’ were calculated. We also performed
sensitivity tests to investigate the prediction performance from current
smoking, ALT and AST.
Step 4: We repeated the Step 3 analyses in two independent cohorts of
whole-blood-derived DNA samples in people of EA (LBC1936 and KORA F4)
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for replication purposes. We also repeated the Step 3 analyses in wholeblood-derived DNA samples of people of AA (the Atherosclerosis Risk in
Communities Study or ARIC) and in the monocyte-derived DNA samples
(the Multi-Ethnic Study of Atherosclerosis or MESA) for both replication and
generalization. The MESA samples included individuals of EA (n = 588), AA
(n = 263) and Hispanic ancestry (n = 400). We used all 1251 individuals in
MESA to estimate the proportion of variance in alcohol consumption that
was explained by the CpGs, but only used the 588 individuals of EA for the
ROC analysis; there were too few heavy drinkers of AA or Hispanic ancestry
for meaningful analysis.
The R statistical software (https://www.r-project.org/) was used for all
analyses. Linear regression was performed using the function ‘lm’ for
unrelated samples and ‘lme’ for family samples to account for family
structure. LASSO was performed using the function ‘glenet’ in the ‘glenet’ R
package with the parameter α = 1 and 10-fold cross-validation to select
CpGs. The ROC analysis used the ‘pROC’ package with the ‘lme’ function for
logistic regression, and then the ‘predict’ function to predict the expected
probability, and ﬁnally the ‘roc’ function to estimate sensitivity and
speciﬁcity of a set of predictors for predicting ‘disease’ versus ‘control’
status.

Meta-analysis to identify DNA methylation signature
The inverse variance-weighted random-effects model28 was used in metaanalysis because of the heterogeneity in levels of alcohol consumption and
population demographics (Table 1). The meta-analysis was performed in
ancestry-stratiﬁed whole-blood-derived DNA samples (n = 9643 EA and
n = 2423 AA) and, secondarily, in combined transethnic samples of
whole-blood and monocyte-derived DNA (n = 13 317). In the meta-analysis,
a CpG was further removed if it was missing in ﬁve or more studies or
its sample size was o20% of the total sample size. We used
Po0.05/440 000 ~ 1 × 10 − 7 to establish signiﬁcance.
We reported alcohol-related CpGs (P ⩽ 1 × 10 − 7) in meta-analysis of
ancestry-stratiﬁed whole-blood-derived DNA samples and in monocytederived DNA samples, and compared alcohol-related CpGs between
ancestries and between whole-blood and monocyte samples. We also
investigated the DNA methylation levels in several genes that were
previously reported to be associated with alcohol metabolism29,30 or
alcohol-related neurotransmission.31–34

DNA methylation in former and never drinkers
To investigate if DNA methylation signals differ between ‘former’ and
‘never’ drinkers, we performed three additional EWAS analyses with DNA
methylation as the outcome variable and three binary traits as the
independent variables (adjusting for age, sex, BMI, batch effects and white
blood cell counts) in the FHS data. The ﬁrst analysis using the binary trait
‘never’ versus ‘former’ as the independent variable, and the other two the
binary traits ‘heavy’ versus ‘never’ or ‘heavy’ versus ‘former’ as the
independent variable. A linear mixed-effects model was used to account
for family structure.
Methylation quantitative trait loci analysis. Methylation quantitative trait
locus analysis (meQTLs) was performed in three cohorts: FHS (n = 2024),
KORA F4 (n = 1799) and the Prospective Investigation of the Vasculature in
Uppsala Seniors (PIVUS) study (n = 920). Genotyping, genotype imputation
and QC details are described in the Supplementary Information. Using data
imputed (allele dosage) to the 1000 Genomes (reference), we selected
cis-SNPs (deﬁned as ± 100 kb) with imputation quality score 40.8 and
minor allele frequency ⩾ 0.05. The meQTL mapping was performed
between the signiﬁcant alcohol-related CpGs (outcomes) and cis-SNPs
(predictors), adjusting for age, sex, BMI, batch effects and white blood
cell counts. The proportion of variance (r2) that can be explained by
cis-SNPs or meQTLs for a CpG was also calculated in association analysis.
We used a linear model in unrelated individuals or a linear mixed-effects
model in family samples to account for familial correlation in association
test between an SNP dosage and DNA methylation. Meta-analysis
used the inverse-variance weighted random-effects model. We used
Po0.05/n to establish signiﬁcance, where n was the number of CpG–SNP
pairs tested.

Association analysis between methylation and gene expression
Gene expression proﬁling and QC in FHS (n = 1924) and KORA F4 (n = 707)
are detailed in the Supplementary Information. To perform the association
analysis, the FHS samples were divided into discovery (n = 966) and
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replication (n = 958) sets by independent pedigrees. In both FHS and KORA
F4 samples, residuals of gene expression levels (ResidGene) or CpG β-values
(ResidCpG) were obtained by adjusting for age, sex, BMI, batch effects and
white blood cell counts. Here batch effects and cell proportion differentials
(if calculated) were expression-speciﬁc or methylation-speciﬁc values. The
association analysis was then performed between ResidGene and ResidCpG.
A linear model was used in unrelated samples and a linear mixed model
was used in family data to account for family structure. The proportion of
variance in a transcript that was explained by a CpG was also calculated.
Because FHS and KORA F4 used different expression arrays, we only used
CpG–gene name pairs that could be matched between the two studies.
Therefore, we used the Z-score method35 for meta-analysis. We used
Po0.05/n to establish statistical signiﬁcance, where n was the number of
CpG-gene transcript pairs tested.

Functional inference and pathway analysis
Genomic features of the alcohol-related CpGs. The genomic location of a
CpG provides functional insight into regulatory features.36 According to
the annotation ‘HumanMethylation450_15017482_v.1.2.csv’ provided by
Illumina, we compared the enrichment or depletion of several genomic
features, including CpG islands, CpG shores and shelves, enhancers, DNA
hypersensitivity sites and promoters in the set of alcohol-related CpGs
(Po 1 × 10 − 7) compared with the background universe of all CpG probes
assessed on the microarray that passed QC. The difference in proportions
of a genomic feature was compared by the Fisher’s two-sided test.
Gene ontology enrichment analysis and functional inference. We performed Gene Ontology (http://geneontology.org/page/go-enrichmentanalysis) enrichment analysis for the genes that were annotated to the
signiﬁcant alcohol-related CpGs. We also examined the genes whose
expression levels were signiﬁcantly associated with the signiﬁcant alcoholrelated CpGs.

RESULTS
A methylation biomarker of alcohol consumption
The meta-analysis of the discovery set that included the wholeblood-derived DNA of individuals of EA from eight cohorts
(n = 6926; Table 1) identiﬁed 361 CpGs at Po 5 − 10 − 6. Of these
361 CpGs, 333 are on the new Inﬁnium MethylationEPIC BeadChip.
Using the FHS cohort as the training set, we selected 5 (s = 0.12),
23 (s = 0.08), 78 (s = ‘lambda.1se’) and 144 (s = ‘lambda.min’) CpGs
out of the 333 CpGs with the LASSO regression (see Materials and
Methods). All CpGs in the smaller lists are subsets of the largest set
of 144 CpGs (s = ‘labmda.min’) (Supplementary Table 1). All
selected CpGs were available in MESA and ARIC. Five CpGs in the
144 set and one in the 78 CpG set were unavailable in KORA F4
and LBC1936 (Supplementary Table 1).
The most parsimonious set of 5 CpGs explained a substantial
proportion of interindividual variance in alcohol consumption in
KORA F4 (6.4%), LBC1936 (10.4%), ARIC (5.2%), MESA (9.9%) and
FHS (15.0%). The addition of more CpGs yielded larger proportions
of explained variance in alcohol consumption. The largest set (144
CpGs) explained 13.1 (KORA F4), 12.0 (LBC1936), 13.8 (ARIC), 13.1
(MESA) and 27.3% (FHS) of variance in alcohol consumption
(Table 2). Because the FHS was used as the training cohort to
select CpGs, the estimated variance values obtained in the FHS
were more optimistic compared with those obtained in the four
replication cohorts.
In ROC analysis of ‘disease’ versus ‘control’ status (see Materials
and Methods), including any CpGs in addition to clinical variables
(age, sex and BMI) (the ‘Full’ model) resulted in a larger AUC value
compared with the model with only clinical variables (the ‘Null’
model). The models with the two smaller sets of CpGs (5 CpGs and
23 CpGs) yielded good prediction (AUCFull 40.80) in all ﬁve
cohorts for discriminating heavy drinkers versus non-drinkers; the
models with the two larger sets of CpGs (78 CpGs and 144 CpGs)
gave good prediction (AUC40.80) in all ﬁve cohorts for
discriminating heavy drinkers versus non-drinkers/light drinkers/
at-risk drinkers, or in discriminating at-risk drinkers versus

Table 2. The proportion of variance in alcohol consumption
explained by DNA methylation
Study

KORA F4
LBC1936
ARIC
MESA
FHS

Variance explained (%)
Null

5 CpGs

23 CpGs

78 CpGs

144 CpGs

12.5
9.9
20.0
11.6
7.8

6.4
10.4
5.2
9.9
15.0

7.4
11.1
6.0
10.5
18.9

11.4
12.2
12.4
11.7
24.6

13.1
12.0
13.8
13.1
27.3

Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; BMI, body
mass index; CpG, cytosine-phosphate-guanine dinucleotide; FHS, Framingham Heart Study; KORA F4, Cooperative Health Research in the Region of
Augsburg; LASSO, least absolute shrinkage and selection operator;
LBC1936, The Lothian Birth Cohort 1936; MESA, Multi-Ethnic Study of
Atherosclerosis. The meta-analysis using the whole-blood-derived DNA of
individuals of European ancestry from eight discovery cohorts (n = 6926,
see Materials and methods) excluding KORA F4 and LBC1936 identiﬁed 361
CpGs with P o5 × 10 − 6. Of these 361 CpGs, 333 are on the new Inﬁnium
MethylationEPIC BeadChip. Using the FHS data as the training set, we
selected 5 (s = 0.12), 23 (s = 0.08), 78 (s = ‘lambda.1se’) and 144 (s =
‘lambda.min’) CpGs with the LASSO regression (see Materials and
Methods). The testing cohorts included two cohorts of European ancestry
with the whole-blood-derived DNA samples (KORA F4 and LBC1936), the
African ancestry cohort with the whole-blood-derived DNA samples (ARIC)
and the cohort of monocyte-derived DNA samples (MESA) of mixed
ancestry (see Table 1). We estimated the proportion of variance in alcohol
consumption explained by a list of CpGs as the difference of adjusted R2using a linear regression model that included age, sex and BMI (the ‘Null’
model) and a model that included a list of CpGs in addition to age, sex and
BMI. All selected CpGs were available in MESA and ARIC. Five CpGs in the
144 set and one CpG in the 78 set were unavailable in KORA F4 and
LBC1936 (see Supplementary Table 1). The estimated variance values using
the FHS data are more optimistic compared with those obtained for the
four replication cohorts.

non-drinkers (Figure 2 and Supplementary Figure 1). For example,
the addition of the 144 CpGs to the null model yielded a high AUC
for discriminating heavy drinkers versus non-drinkers (AUCFull =
0.90–0.99 compared with AUCNull = 0.63–0.80) and heavy drinkers
versus light drinkers (AUCFull = 0.85–0.99 compared to AUCNull =
0.53–0.61) across the ﬁve cohorts; the addition of 78 CpGs to the
null model yielded slightly lower AUC values compared with
addition of the 144 CpGs: AUCFull = 0.88–0.99 in discriminating
heavy drinkers versus non-drinkers and AUCFull = 0.82–0.96 in
discriminating heavy drinkers versus light drinkers. It is worth
noting that in discriminating heavy drinkers versus non-drinkers/
light drinkers, the performance of the 144 CpGs and 78 CpGs was
better in MESA and LBC1936 compared with that in FHS (the
training cohort); but the performance of these two sets of CpGs
was lower in KORA F4 and ARIC (Figure 2). Unavailability of a few
CpGs in LBC1936 did not seem to affect discrimination (Table 2
and Figure 2).
Current smoking explained a very small proportion of variance
in alcohol consumption. For example, the change in adjusted
R2 = 0.003 in FHS and 0.01 in MESA when current smoking was
included in the model in addition to age, sex and BMI. Similarly,
ALT or AST explained a small proportion of variance in alcohol
consumption in FHS: the change in adjusted R2 = 0.004 when
either ALS or AST was added to the null model. Therefore, neither
ALT nor AST was a good biomarker for alcohol consumption,
which was conﬁrmed in ROC analysis: AUCNull+ALT or Null+AST = 0.67
when ALT or AST was added in the null model (AUCNull = 0.66) in
discriminating heavy drinkers versus non-drinkers in FHS.
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Association between DNA methylation and alcohol intake
C Liu et al

1.0

1.0

0.9

0.9

Area under the curve

Area under the curve

428

0.8

0.7
ARIC
FHS
KORA F4
LBC1936
MESA

0.6

0.5
Null

5−CpGs

23−CpGs

78−CpGs

0.8

0.7
ARIC
FHS
KORA F4
LBC1936
MESA

0.6

0.5

144−CpGs

Null

5−CpGs

23−CpGs

78−CpGs

144−CpGs

Figure 2. A biomarker of heavy alcohol drinking. Four sets of cytosine-phosphate-guanine dinucleotides (CpGs) were selected at s = 0.12
(5 CpGs), s = 0.08 (23 CpGs), s = ‘lambda.1se’ (78 CpGs) and s = ‘lambda.min’ (144 CpGs) using least absolute shrinkage and selection operator
(LASSO) in the Framingham Heart Study (FHS) cohort (the training cohort). ROC analysis was performed to classify heavy drinkers versus nondrinkers (left ﬁgure) and heavy drinkers versus light drinkers (right ﬁgure). ‘Non-drinkers’ were subjects with no alcohol consumption (i.e., g
per day = 0); ‘light drinkers’ were subjects who consumed 0o g per day ⩽ 28 in men and 0 og per day ⩽ 14 in women; ‘heavy drinkers’ were
subjects who consumed ⩾ 42 g per day in men and ⩾ 28 g per day in women. ARIC, The Atherosclerosis Risk in Communities study; KORA F4,
The Cooperative Health Research in the Region of Augsburg study; LBC1936, The Lothian Birth Cohort 1936; MESA, The Multi-Ethnic Study of
Atherosclerosis.
Table 3.

The 30 most signiﬁcant CpGs in relation to continuous alcohol intake in meta-analysis of whole-blood samples of European ancestry

IlmnID

UCSC gene Chr

cg03523740
cg20970369
cg16246545
cg19266329
cg19238380
cg11194994
cg07502661
cg00883689
cg13729116
cg25518868
cg05593667
cg20732076
cg06189038
cg12873476
cg03599037
cg06603309
cg11376147
cg00271311
cg09448652
cg09737197
cg02583484
cg23654112
cg08916477
cg06469895
cg00574412
cg21626848
cg08677210
cg15253293
cg24217948
cg13127741

TXLNA
DENND2D
PHGDH
LMNA
PEA15
SPTBN1
LETM1
DIAPH1
TRERF1
GAL3ST4
C10orf58
KCNQ1
SLC43A1
CNTF
SNORD30
CPT1A
HNRNPA1
TBC1D24
SEPT1
TERF2
ABHD15
SC65
MSI2
SETBP1
COMMD7

1
1
1
1
1
1
2
2
4
5
6
6
7
8
10
11
11
11
11
11
12
16
16
16
17
17
17
17
18
20

Position

P-value

β

S.e.

32 645 027
111 744 108
120 255 941
145 456 128
156 093 948
160 175 974
43 398 339
54 802 904
1 859 262
140 984 057
35 490 744
42 335 231
99 767 134
142 402 728
82 172 508
2 724 144
57 261 198
58 389 290
62 621 367
68 607 675
54 677 008
2525 928
30 391 350
69 418 206
27 892 866
39 969 267
55 550 613
79 366 853
42 261 980
31 331 821

4.4E − 15
3.2E − 12
1.5E − 12
1.7E − 13
2.2E − 12
7.3E − 15
2.6E − 12
3.2E − 12
6.7E − 18
2.3E − 12
4.4E − 16
1.5E − 12
4.6E − 13
2.8E − 12
4.5E − 13
2.7E − 14
9.8E − 13
1.6E − 13
1.3E − 12
5.0E − 13
1.6E − 19
3.0E − 13
4.0E − 13
1.5E − 13
1.1E − 12
3.1E − 15
3.3E − 12
1.1E − 15
2.1E − 12
3.1E − 12

− 0.00022
− 0.00023
− 0.00061
− 0.00028
− 0.00029
− 0.00017
− 0.00019
− 0.00028
− 0.00018
− 0.00012
− 0.00025
− 0.00015
− 0.00016
− 0.00023
− 0.00014
0.00017
− 0.00026
− 0.00022
− 0.00026
− 0.00016
− 0.00039
− 0.00014
− 0.00016
− 0.00020
− 0.00017
− 0.00023
− 0.00013
− 0.00014
− 0.00028
− 0.00023

2.8E − 05
3.3E − 05
8.6E − 05
3.8E − 05
4.2E − 05
2.2E − 05
2.7E − 05
4.1E − 05
2.1E − 05
1.8E − 05
3.1E − 05
2.1E − 05
2.2E − 05
3.3E − 05
1.9E − 05
2.2E − 05
3.6E − 05
2.9E − 05
3.6E − 05
2.2E − 05
4.4E − 05
1.9E − 05
2.2E − 05
2.8E − 05
2.3E − 05
2.9E − 05
1.9E − 05
1.7E − 05
3.9E − 05
3.3E − 05

UCSC CpG islands

Relation to UCSC CpG
island

Chr 1:32 645 154–32 645 814
Chr 1:111 746 337–111 747 303
Chr 1:120 254 844–120 255 499

N_Shore
N_Shelf
S_Shore

Enhancer

TRUE
TRUE
Chr 1:160 175 132–160 175 702
Chr 2:43 398 040–43398276

S_Shore
S_Shore

Chr 4:1 857 065–1 858 887

S_Shore

TRUE
TRUE
TRUE
Chr
Chr
Chr
Chr

7:99 768 884–99 769 559
8:142 401 533 − 142 402 494
10:82 168 064–82 168 917
11:2 720 410–2 722 087

N_Shore
S_Shore
S_Shelf
S_Shelf

Chr
Chr
Chr
Chr
Chr
Chr
Chr
Chr

11:62 623 359–62 623 877
11:68 608 155–68609419
12:54 673 322–54 673 550
16:2 521 086–2 525 929
16:30 389 035–30 390 631
16:69 419 316–69 420 086
17:27 893 086–27 896 078
17:39 967 407–39 968 604

N_Shore
N_Shore
S_Shelf
Island
S_Shore
N_Shore
N_Shore
S_Shore

Chr 17:79 366 806–79374742
Chr 18:42 258 983–42 260 795
Chr 20:31 330 957–31 331 410

Island
S_Shore
S_Shore

TRUE
TRUE
TRUE

TRUE
TRUE

Abbreviation: CpG, cytosine-phosphate-guanine dinucleotide; S.e, standard error. Epigenome-wide association and meta-analysis of the continuous alcohol
intake was performed using all whole-blood-derived DNA samples of European ancestry. The DNA methylation proportion was the outcome variable, grams
alcohol consumed per day (g per day) was the predictor variable, adjusting for age, sex, body mass index, technical covariates and white blood cell counts. The
inverse-variance weighted random-effects model was performed in meta-analysis (See Supplementary Table 2 for a full set of signiﬁcant CpGs). The annotation
“HumanMethylation450_15017482_v.1.2.csv” provided by Illumina was used to annotate the CpG loci.

Epigenome-wide methylation signature of alcohol intake
In the main text, we reported ancestry-stratiﬁed meta-analysis
(P o 1 × 10 − 7) for whole-blood-derived DNA in individuals of EA
Molecular Psychiatry (2018), 422 – 433

(n = 9643) and AA (n = 2423) (Table 1) using an inverse-variance
weighted random-effects model (Figure 1). Meta-analysis of
pooled samples (n = 13 317) and several sensitivity tests including
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Figure 3. Meta-analysis of epigenome-wide association of alcohol intake in European ancestry (EA) whole-blood samples: the Manhattan plot
(top) and the volcano plot (bottom). The DNA methylation proportion was the outcome variable, grams alcohol consumed per day (g per day)
was the predictor variable, adjusting for age, sex, body mass index, technical covariates and white blood cell counts. The inverse-variance
weighted random-effects model was performed in meta-analysis using all whole blood DNA samples of EA.

EWAS in only drinkers and the investigation of whether or not
prevalent CVD or cancer confound the relationship between DNA
methylation and alcohol consumption are included in the
Supplementary Information.
Genome-wide pattern of DNA methylation associated with alcohol
consumption. We identiﬁed hundreds of CpGs (P o1 × 10 − 7)
whose differential methylation across the genome was associated
with alcohol intake: 363 CpGs in whole-blood samples of
individuals of EA (Table 3, Figure 3 and Supplementary Table 2),
165 CpGs in whole-blood samples of individuals of
(AA (Supplementary Table 3 and Supplementary Figure 2) and
62 CpGs in monocyte-derived DNA samples (Supplementary Table
4 and Supplementary Figure 3). Additional CpGs at P o 1 × 10 − 4
are reported in Supplementary Tables 5–7. Genomic inﬂation in
meta-analysis was estimated at ~ 10% or less, indicating low
additional risk of false-positive ﬁndings (Supplementary Table 8).
The majority of the alcohol-related CpGs exhibited an inverse
relationship between higher alcohol intake and lower methylation
(Supplementary Tables 2–4).
Fewer alcohol-related CpGs (P o 1 × 10 − 7) were identiﬁed in the
analysis of the categorical alcohol trait that compared light
drinkers, at-risk drinkers and heavy drinkers with non-drinkers
(Supplementary Tables 9–11 and Supplementary Figures 4–6).
Additional CpGs at P o 1 × 10 − 4 are included in Supplementary
Tables 12–14. The majority of the alcohol-related CpGs identiﬁed
in the analysis of the categorical alcohol trait (Supplementary
Tables 9–11) were also signiﬁcant or nominally signiﬁcant in the
association with the continuous alcohol consumption trait
(Supplementary Tables 2–4).

Transethnic replication of methylation signatures
Of the 363 alcohol-related CpGs in EA samples, 56 had P o 0.00014
(0.05/363) in AA samples; of the 165 alcohol-related CpGs in AA
samples, 59 had P o 0.00030 (0.05/165) in EA samples. Effect
estimates of the 518 (union of 363 and 165) unique CpGs were
moderately correlated between EA and AA whole-blood samples:
Pearson’s correlation r = 0.64 (Figure 4a). For example, cg11376147
in solute carrier family 43 (SLC43A1) displayed P o 1 × 10 − 7 in both
EA and AA samples from whole blood (Figure 4b).
Methylation signature in whole-blood- and monocyte-derived
DNA
Of the 363 alcohol-related CpGs in EA whole blood samples, 57
replicated (Po0.00014; 0.05/363) in monocyte samples. Of the 62
alcohol-related CpGs in monocytes, 13 replicated (Po0.0008; 0.05/62)
in whole-blood EA samples. The Pearson’s correlation was 0.72 for
the 417 unique (union of 363 and 62) CpGs between EA wholeblood samples and monocyte samples (Figure 4c). For example,
cg11376147 in SLC43A1 also displayed Po 1 × 10 − 7 for association
with alcohol consumption in monocyte-derived DNA (Figure 4b).
Similar DNA methylation pattern in former and never drinkers
Based on alcohol consumption at prior examinations in FHS, we
classiﬁed the 693 non-drinkers (Table 1) into ‘never’ (n = 107) and
‘former’ drinkers (n = 586). Furthermore, among the 586 ‘former’
drinkers, 91 were ‘former’ heavy drinkers, 66 were ‘former’ at-risk
drinkers and 429 were ‘former’ light drinkers. The EWAS using the
binary trait ‘never’ versus ‘former’ as the independent variable did
Molecular Psychiatry (2018), 422 – 433
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Figure 4. Comparison of regression coefﬁcients of the signiﬁcant cytosine-phosphate-guanine dinucleotides (CpGs) in association analysis of
the continuous alcohol trait (g per day): (a) between European and African whole-blood samples; (b) the Forest plot of effect estimates and
standard errors of cg11376147 in all study cohorts; and (c) between European whole-blood and CD14+ monocyte samples. (a) Includes a list
of CpGs with P o1 × 10 − 7 in EA or AA whole-blood samples and (c) includes a list of CpGs with P o1 × 10 − 7 in EA whole-blood samples or in
monocyte samples of mixed ancestries. The Pearson’s correlation was r = 0.64 between the effect estimates in (a) and r = 0.72 in (c). MM,
monocyte, mixed ancestries; WB AA, whole blood, African ancestry; WB EA, whole blood, European ancestry.

not yield any signiﬁcant results (Supplementary Figure 7). We
compared the EWAS results between ‘heavy’ versus ‘never’ and
‘heavy’ versus ‘former’. For genome-wide methylation loci, the
correlation was 0.32 for regression coefﬁcients and 0.20 for –log10
(P-values); for loci with P–value o 1 × 10 − 7 (n = 92) in either
‘heavy’ versus ‘never’ or ‘heavy’ versus ‘former’ drinkers, the
correlation was 0.91 for regression coefﬁcients and 0.88 for –log10
(P-values) (Supplementary Figure 8). These results indicate that
DNA methylation levels were not considerably different between
‘never’ drinkers and ‘former’ drinkers and that DNA methylation
changes due to heavy alcohol consumption revert after
individuals abstained from alcohol intake for several years
(FHS examinations were ~ 4 years apart).
Evaluation of smoking in the association between alcohol intake
and DNA methylation
It is unclear if current cigarette smoking confounds the association
between DNA methylation and alcohol intake, or if smoking and
alcohol intake are associated with common CpGs. Therefore, we
performed an analysis using smoking as an additional covariate in
the EWAS (see Materials and methods). We found that some
alcohol-related CpGs displayed a large change (410% change) in
Molecular Psychiatry (2018), 422 – 433

the size of their regression coefﬁcients when smoking was
included as an additional covariate in the analysis of wholeblood-derived DNA samples in individuals of EA (35 of the 363
CpGs at P o 1 × 10 − 7) and AA (92 of the 165 CpGs at P o1 × 10 − 7)
ancestries, but none of the CpGs in the monocyte-derived DNA
samples changed appreciably after additionally adjusting for
smoking (Supplementary Tables 2–4). Several of the identiﬁed
CpGs that displayed a large change in effect estimates following
adjustment for smoking have been previously reported to be
associated with smoking, including the CpGs in the aryl-hydrocarbon receptor repressor37,38 (Supplementary Tables 5 and 6). We
excluded the 35 CpGs that showed large change in effect estimates
after adjusting for smoking (Supplementary Table 2) in subsequent
analyses that were performed using the whole-blood-derived DNA
samples from individuals of EA ancestry.
Alcohol metabolism enzymes and alcohol-related DNA methylation.
Several functional DNA sequence variants in the alcohol
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) family
of genes are known for their effects on alcohol metabolism.29,30
We checked CpGs in the introns, exons and regulatory regions in
these gene families according to the annotation provided by
Illumina. No CpGs in the ADH (30 CpGs in seven genes) or ALDH
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Figure 5. The γ-aminobutyric acid-A (GABA-A) receptor, delta (GABRD): the associations of the 36 cytosine-phosphate-guanine dinucleotides
(CpGs) within GABRD, genomic and regulatory features and correlation of methylation measurements. The results were obtained in metaanalysis of the association analysis of 9643 whole-blood-derived DNA samples of European ancestry (EA) individuals. The correlation of these
36 CpGs was calculated using the methylation measurements at 36 CpGs, adjusting for age, sex, technical covariates and white cell blood
counts in the Framingham Heart Study samples.

(340 CpGs in 19 genes) loci were differentially methylated
(P o 1 × 10 − 7) in relation to alcohol use (Supplementary Tables
5–7, 15, 16).
Neurotransmitter receptors and alcohol-related DNA methylation
γ-aminobutyric acid (GABA), a major neurotransmitter, and its
receptors are known for their involvement in the acute and
chronic behavioral effects of ethanol in humans and animal
models.31–34 A total of 607 CpGs were mapped to introns, exons
and regulatory regions of 22 GABA receptor genes (Supplementary
Table 17). In meta-analysis of whole-blood-derived DNA samples
of EA individuals, cg04781796 (βalcohol = 0.0002, P = 1.9 × 10 − 9) and
cg09577455 (βalcohol = − 0.0015, P = 3.0 × 10 − 8) were signiﬁcantly
associated with alcohol consumption (Supplementary Table 2).
However, neither of these CpGs was signiﬁcant in whole-bloodderived DNA samples of people of AA (cg04781796:
βalcohol = 0.00004, P = 0.17; cg09577455: βalcohol = − 0.00003,
P = 0.0016) or in monocyte-derived DNA samples (cg04781796:
βalcohol = 0.0001, P = 0.22; cg09577455: βalcohol = − 0.00002,
P = 0.82). The CpG cg04781796 is located in a CpG island (Chr 1:
1 959 414–1 959 867, hg19) that is intronic to the GABA-A
receptor, delta (GABRD; Figure 5); and cg09577455 is located in
the north shore of a CpG island (Chr 6: 29 595 298–29 595 795,
hg19) that is intronic to GABA-B receptor subunit 1 (GABBR1, Chr 6;
Supplementary Figure 9). CpG cg04781796 displayed higher
methylation in relation to greater alcohol intake, whereas
cg09577455 displayed lower methylation levels in association
with increased alcohol intake.

Genetic basis underlying the signiﬁcant alcohol-related CpGs
We tested for association of the methylation levels of 328 CpGs
(selected in meta-analysis of DNA of EA individuals in
Supplementary Table 2) with nearby SNPs (±100KB, cis-SNPs or
cis-meQTLs) in three cohorts (total number of individuals = 4623
from FHS, KORA F4 and PIVUS) (see Materials and methods). A
total of 105 759 SNP-CpG pairs were formed from these 328 CpGs
with cis-SNPs. Meta-analysis of the FHS, KORA F4 and PIVUS
samples identiﬁed 14 160 SNP–CpG pairs (170 unique CpGs and
12 857 unique cis-SNPs) at P o0.05/105 759 ~ 4.7 × 10 − 7
(Supplementary Table 18). We found that 16 CpGs had meQTLs
that explained 20–61% of interindividual variance in methylation
at the corresponding CpG (Supplementary Table 18). None of
these 12 857 signiﬁcant meQTLs was associated with alcoholrelated traits (P o 1 × 10 − 8) by querying these signiﬁcant meQTLs
in the Catalog of Published Genome-Wide Association Studies
(http://www.genome.gov/gwastudies/, latest version released on
May 12, 2015).
Association of alcohol-related DNA methylation with gene
expression
We tested for associations between the 328 alcohol-related CpGs
and blood gene expression levels in FHS (n = 1924) and KORA F4
(n = 707) for genes within 1 Mb of these 328 CpGs in both studies
(see Materials and methods). Meta-analysis identiﬁed 110 CpG–
gene pairs (83 unique CpGs and 100 unique genes) at Po 0.05/7111 = 7 × 10 − 6, where 7111 is the number of tested CpG–gene
pairs (Supplementary Table 19). Of the 110 signiﬁcant pairs, 86
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(78%) displayed negative correlations between methylation and
mRNA levels.
We examined associations of the two signiﬁcant alcohol-related
CpGs in GABA receptor genes with expression of cis genes. At the
GABRD locus, cg04781796 was not associated with expression of
any genes in blood within 1 Mb, whereas cg09577455 in the
GABBR1 locus was associated with the expression of the
interferon-induced transmembrane protein 4 pseudogene
(IFITM4P; P = 2.4 × 10 − 6) (Supplementary Table 19). Owing to the
important role of GABA receptors in alcohol-induced signal
transduction and immune functions, we carried out additional
association analyses between these two CpGs and gene
transcripts beyond 1 Mb or on different chromosomes (i.e. trans
associations) in both FHS and KORA F4. Of the 35 746 association
pairs,
228
showed
signiﬁcant
association
(P o 0.05with
methylation
of
cg04781796
/35 746 ~ 1.4 × 10 − 6)
(Supplementary Table 20) and 13 transcripts were associated with
cg09577455 (Supplementary Table 21) in the meta-analysis.
Functional inference and pathway analysis
Genomic features of the alcohol-related CpGs. We found that the
328 alcohol-related CpG set was signiﬁcantly enriched for CpG
island shores (48% versus 24%, P = 7.3 × 10 − 12) and enhancers
(29% versus 22%, P = 0.003) compared with all CpGs that passed
QC in meta-analysis. In contrast, the 328 alcohol-associated CpG
set was signiﬁcantly depleted for CpG islands (16% versus 32%,
P = 1.1 × 10 − 6) and promoters (3% versus 7%; P = 0.009)
(Supplementary Table 22). There was no signiﬁcant difference in
proportions of CpG island shelves and DNase I hypersensitive sites
among the 328 alcohol-associated CpGs.
We found similar enrichment and depletion for the 144 CpGs
that were selected in biomarker analysis. These 144 CpGs were
signiﬁcantly enriched for CpG island shores (47% versus 24%,
P = 4.5 × 10 − 11) and enhancers (30% versus 22%, P = 0.002), but
signiﬁcantly depleted for CpG islands (13% versus 32%,
P = 1.0 × 10 − 6) and promoters (2% versus 7%, P = 0.007).
Gene ontology enrichment analysis and functional inference.
A total of 257 genes were annotated to the 328 alcohol-related CpGs.
These 257 genes were enriched for 95 biological processes
(Bonferroni-corrected Po0.05, Supplementary Table 23) including
regulation of transcription, macromolecule metabolic process and
cellular response to stress and chemicals. The most signiﬁcant
biological process constituted 32 genes enriched (44-fold) for
‘negative regulation of transcription from RNA polymerase II
promoter’ (Bonferroni-corrected P = 2.3 × 10 − 7; Supplementary Table
24). For the 100 cis genes whose transcript levels were signiﬁcantly
associated with 83 CpGs (Supplementary Table 19), the analysis of
biological processes showed that the most signiﬁcantly enriched
process was ‘negative regulation of transposition’ (Bonferronicorrected P = 8.0 × 10 − 4, Supplementary Table 25). Other enriched
processes included defense response to virus (P = 0.006) and DNA
cytosine deamination (P = 0.02). The trans-transcripts that were
signiﬁcantly associated with cg04781796 (GABRD) were enriched for
pathways that are involved in immune functions such as lymphocyte
activation (P = 1.1 × 10 − 11) and immune system process
(P = 3.2 × 10 − 11; Supplementary Table 26). The trans-transcripts that
were associated with cg09577455 in GABBR1 were also enriched for
immune response (P = 0.015; Supplementary Table 27).
DISCUSSION
We conducted an EWAS of alcohol intake in 13 cohorts including
13 317 samples of whole-blood or monocyte-derived DNA from
individuals of mostly EA and AA. We identiﬁed hundreds of
differentially methylated CpGs (P o 1 × 10 − 7) in relation to alcohol
consumption. More than half of the alcohol-related methylation
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sites were associated with cis-genetic variants, supporting the
hypothesis that DNA methylation sites are sensitive to both
environmental and genetic inﬂuences.39 In addition, we developed
a robust and replicable DNA methylation biomarker that provides
substantial discrimination for current heavy alcohol intake.
A set of 144 CpGs was highly predictive for discriminating
current heavy alcohol drinkers from non-drinkers (AUC40.90) in
all replication cohorts. As a biomarker, these selected CpGs
performed better than commonly clinical variables and biomarkers in discriminating current heavy alcohol drinking.7 This is in
line with the discriminatory power of DNA methylation for other
complex traits, such as BMI.40 Therefore, a whole-blood DNA
methylation biomarker has the potential to be developed into a
commercially marketable diagnostic test to detect current heavy
alcohol consumption. Such a test could be useful to supplement
and validate self-reported alcohol consumption data, or in a
forensic setting, or as a screening test.
The biomarker analysis and ancestry-stratiﬁed meta-analysis
showed that a number of DNA methylation sites displayed
consistent alcohol-related effects in whole-blood samples of
people of EA and AA. However, the transancestry comparison
also showed the lack of similarities of many CpG sites. We propose
three explanations. First, some DNA methylation sites are truly
ancestry-speciﬁc, which needs to be conﬁrmed by future studies.
Second, sample heterogeneity in alcohol consumption may
explain a part of the non-concordance for some CpGs in AA and
EA groups. For example, in ARIC, ~ 76% individuals were nondrinkers and ~ 17% were heavy drinkers, whereas in most EA
cohorts, 460% of participants were light drinkers. Third, a large
difference in sample sizes (EA n = 9643 and AA n = 2423) and the
probability in sampling are additional reasons for the lack of
replication when a Bonferroni-corrected threshold was used.
We provide evidence that alcohol-related DNA methylation is
associated with gene expression in whole blood. Of note, we
showed that whole-blood epigenetic changes in GABA receptor
genes were signiﬁcantly associated with the expression levels of a
number of genes that are involved in immune function supporting
the recent ﬁndings that GABA and its receptor have effects on
immune cells through cross-talk between the nervous system and
the immune system.41 However, as our data are cross-sectional and
observational in nature, further research is needed to determine if
these changes are causal or reactive. The gene set analysis is based
on a crucial and unrealistic independence assumption pertaining to
genes, which may not be valid for biological processes. Therefore,
we should interpret the signiﬁcant P-values with caution.42
In addition to the cross-sectional nature of this study, our
ﬁndings were limited to DNA samples from mostly middle- and
older-aged individuals of EA and AAs. Future studies are needed
to investigate the generalizability of our ﬁndings to other age
groups and ancestries. Nevertheless, as the largest study of its
kind, this work identiﬁed a robust alcohol-related DNA methylation
signature in blood and demonstrated that the alcohol-related
methylation changes in blood are of sufﬁcient magnitude to be
interesting clinically, which addresses a gap within the ﬁeld. Future
studies are warranted to investigate whether alcohol-related
methylation in blood affects GABA neurotransmitter function in
the brain and to investigate how alcohol-related epigenetic
modiﬁcations inﬂuence the beneﬁcial and detrimental downstream
consequences of alcohol-related health outcomes. Identifying how
alcohol-induced DNA methylation changes modify gene expression
and result in pathway activation or suppression may shed light on
the molecular basis of alcohol addiction and alcohol-related
diseases and reveal new therapeutic strategies.
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